{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003241","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.012654+00:00","generated_at":"2026-05-24T11:29:40.064221+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bio-Path pre-clinical data shows BP1001-A restores insulin sensitivity, supporting obesity/T2D potential","bullets":["BP1001-A attenuated palmitic acid-induced insulin resistance in C2C12 myoblasts and myotubes.","Final pre-clinical mouse model study expected H1 2025; IND filing planned by year-end.","BP1001-A downregulates Grb2 expression to increase insulin sensitivity in muscle cells.","CEO cites need for alternative glucose-lowering treatments in obese T2D patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003241","json":"https://secwatch.observer/filing/0001558370-25-003241.json","markdown":"https://secwatch.observer/filing/0001558370-25-003241.md","text":"https://secwatch.observer/filing/0001558370-25-003241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837025003241/0001558370-25-003241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837025003241/bpth-20250318x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:29:40.064221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}